InvestSMART

AFT Pharmaceuticals Limited (ASX: AFP) - Announcements

- Current share price for AFP : $3.650

ASX company news and announcements for AFT Pharmaceuticals Limited (AFP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All AFT Pharmaceuticals Limited (AFP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than AFT Pharmaceuticals Limited (AFP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for AFT Pharmaceuticals Limited (AFP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$383 Disclosure of Directors and Senior Managers Relevant Interes 22 Dec 2021 7:31AM $3.930 $3.650 fallen by 7.12%
$383 Application for quotation of securities - AFP 9 Dec 2021 7:31AM $4.210 $3.650 fallen by 13.30%
$383 AFT welcomes Australian Federal Court appeal success 9 Dec 2021 7:30AM $4.210 $3.650 fallen by 13.30%
$383 amended capital notice 7 Dec 2021 2:50PM $4.300 $3.650 fallen by 15.12%
$383 Application for quotation of securities - AFP 7 Dec 2021 12:54PM $4.300 $3.650 fallen by 15.12%
$383 capital change notice 7 Dec 2021 11:56AM $4.300 $3.650 fallen by 15.12%
$383 Presentation Slide 16 Correction 18 Nov 2021 7:38AM $4.580 $3.650 fallen by 20.31%
$383 211118 AFT Interim Announcement FY2022 App2 18 Nov 2021 7:31AM $4.580 $3.650 fallen by 20.31%
$383 211118 AFT Interim Financial Statements FY22 18 Nov 2021 7:30AM $4.580 $3.650 fallen by 20.31%
$383 211118 AFT FY 22 Interim Result Investor Presentation 18 Nov 2021 7:30AM $4.580 $3.650 fallen by 20.31%
$383 211118 AFT 1H FY22 Market Release 18 Nov 2021 7:30AM $4.580 $3.650 fallen by 20.31%
$383 FDA confirms earlier than expected PDUFA date for Maxigesic 15 Nov 2021 7:35AM $4.500 $3.650 fallen by 18.89%
$383 AFT appoints McPhersons as Singapore distributor 5 Nov 2021 7:30AM $4.320 $3.650 fallen by 15.51%
$383 US FDA accepts Maxigesic IV New Drug Application 1 Nov 2021 7:31AM $3.900 $3.650 fallen by 6.41%
$383 Maxigesic IV registered in the UK and Ireland 19 Oct 2021 9:03AM $3.760 $3.650 fallen by 2.93%
$383 half year interim results announcement 18 Nov 2021 12 Oct 2021 7:31AM $3.900 $3.650 fallen by 6.41%
$383 AFT further extends Maxigesic footprint strengthens EU 21 Sep 2021 7:31AM $3.890 $3.650 fallen by 6.17%
$383 Change of Capital notice 6 Sep 2021 9:18AM $3.890 $3.650 fallen by 6.17%
$383 ASM 2021 results 6 Aug 2021 12:16PM $4.320 $3.650 fallen by 15.51%
$383 ASM presentation 6 Aug 2021 7:44AM $4.320 $3.650 fallen by 15.51%
$383 ASM chairs address 6 Aug 2021 7:38AM $4.320 $3.650 fallen by 15.51%
$383 New clinical study Novaliq NovaTears Omega-3 eye drops 29 Jul 2021 7:30AM $4.200 $3.650 fallen by 13.10%
$383 Application for quotation of securities - AFP 14 Jul 2021 4:09PM $4.350 $3.650 fallen by 16.09%
$383 D&O Ongoing Disclosure - Louise Clayton 14 Jul 2021 3:59PM $4.350 $3.650 fallen by 16.09%
$383 Capital Change Notice - Issue of ordinary shares 14 Jul 2021 3:51PM $4.350 $3.650 fallen by 16.09%

176 - 200 of 546 results

Page 8 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.